BioGaia AB Stock

Equities

BIOG B

SE0017769995

Pharmaceuticals

Real-time Estimate Cboe Europe 11:17:22 2024-07-22 am EDT 5-day change 1st Jan Change
125 SEK +1.67% Intraday chart for BioGaia AB +1.38% +23.72%
Sales 2024 * 1.43B 134M Sales 2025 * 1.59B 148M Capitalization 12.42B 1.16B
Net income 2024 * 404M 37.8M Net income 2025 * 441M 41.26M EV / Sales 2024 * 7.81 x
Net cash position 2024 * 1.26B 117M Net cash position 2025 * 965M 90.34M EV / Sales 2025 * 7.22 x
P/E ratio 2024 *
30.8 x
P/E ratio 2025 *
28.1 x
Employees 211
Yield 2024 *
5.61%
Yield 2025 *
5.61%
Free-Float 80.06%
More Fundamentals * Estimated data
Dynamic Chart
1 day+0.93%
1 week-1.60%
Current month-0.57%
1 month-1.76%
3 months+2.93%
6 months+16.04%
Current year+21.54%
More quotes
1 week
123.00
Extreme 123
128.00
1 month
121.30
Extreme 121.3
128.00
Current year
101.00
Extreme 101
136.60
1 year
91.45
Extreme 91.45
136.60
3 years
68.88
Extreme 68.88
136.60
5 years
63.00
Extreme 63
136.60
10 years
30.20
Extreme 30.2
136.60
More quotes
Managers TitleAgeSince
Founder 74 89-12-31
Chief Executive Officer 58 23-08-31
Director of Finance/CFO 57 19-11-04
Members of the board TitleAgeSince
Director/Board Member 75 02-12-31
Founder 74 89-12-31
Director/Board Member 68 23-05-04
More insiders
Date Price Change Volume
24-07-22 125.2 +1.79% 43 395
24-07-19 123 -1.76% 38,863
24-07-18 125.2 -1.57% 33,339
24-07-17 127.2 +0.08% 30,501
24-07-16 127.1 +2.91% 196,377

Delayed Quote Nasdaq Stockholm, July 19, 2024 at 12:00 pm EDT

More quotes
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The Company operates worldwide.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
123 SEK
Average target price
150 SEK
Spread / Average Target
+21.95%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIOG B Stock